Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2020 Apr;149(1):37-42.
doi: 10.1002/ijgo.13082. Epub 2020 Jan 8.

Intravenous magnesium sulfate in the management of severe pre-eclampsia: A randomized study of 12-hour versus 24-hour maintenance dose

Emmanuel A Unwaha  1 , Folasade A Bello  1 , Oluwasomidoyin O Bello  1 , Adesina Oladokun  1
Affiliations
Randomized Controlled Trial

Intravenous magnesium sulfate in the management of severe pre-eclampsia: A randomized study of 12-hour versus 24-hour maintenance dose

Emmanuel A Unwaha et al. Int J Gynaecol Obstet. 2020 Apr.

Abstract

Objective: To assess the effectiveness of a 12-hour versus 24-hour intravenous maintenance dose of magnesium sulfate (MgSO4 ) in women with pre-eclampsia, and the maternal and fetal outcomes.

Methods: This was a randomized controlled trial conducted at the labor ward complex of University College Hospital, Ibadan, Nigeria between May and August 2014. Pregnant women with severe pre-eclampsia were randomized to receive a 12-hour versus 24-hour maintenance dose of MgSO4 . Study outcomes were occurrence of seizures, adverse maternal effects, neonatal survival, and admission to the intensive care unit. Data analysis involved descriptive statistics and bivariate analysis using Statistical Package for Social Science (SPSS) version 20.

Results: There were 80 patients randomized to the 12-hour (n=40) and 24-hour (n=40) groups. The participants in the two groups had comparable demographic features. There was no significant difference (P>0.999) between the satisfactory maternal outcome following the 12-hour maintenance dose and the standard 24-hour regimen (95.0% vs 97.5%). Similarly, there was no significant difference (P=0.276) in perinatal mortality in the 12-hour versus 24-hour arm (17.5% vs 12.5%, respectively). No case of eclampsia and maternal death was recorded.

Conclusion: A 12-hour maintenance dose of intravenous MgSO4 in the management of severe pre-eclampsia is effective and safe when compared with the 24-hour maintenance dose.

Keywords: Eclampsia; Magnesium sulfate; Maternal morbidity; Perinatal mortality; Pre-eclampsia; Pregnancy.

PubMed Disclaimer

References

REFERENCES

    1. Ghulmiyyah L, Sibai B. Maternal mortality from pre-eclampsia/eclampsia. Semin Perinatol. 2012;36:56-59.
    1. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet. 2010;376:631-644.
    1. Ugwu E, Dim CC, Okonkwo CD, Nwankwo TO. Maternal and perinatal outcome of severe preeclampsia in Enugu, Nigeria after introduction of Magnesium sulfate. Niger J Clin Pract. 2011;14:418-421.
    1. Gruslin A, Lemyre B. Preeclampsia: Fetal assessment and neonatal outcomes. Best practice and research. Best Pract Res Clin Obstet Gynaecol. 2011;25:491-507.
    1. Bell MJ. A historical overview of pre-eclampsia/eclampsia. J Obstet Gynecol Neonatal Nurs. 2010;39:510-518.

Publication types

Substances

LinkOut - more resources